drug
dalbavancin
Marketedupdated 3mo agoby Allergan Sales LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(0)
nothing on the calendar yet
Trials studying dalbavancin
- phase3Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
- phase3Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 23, 2028
~1.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- May 23, 2028method-of-use (U-3499)US 69001751.8y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that